Transcode TherapeuticsRNAZ
13F holders, Q2 2026 (June 30)8holders
2new positions
2sold out
$6.21avg. 13F price*
At the end of Q2 2026, 8 institutions reported holding Transcode Therapeutics Inc. (RNAZ) in their 13F filings, unchanged from Q1 2026. 2 opened new positions and 2 sold out. The largest holders were Yorkville Advisors Global, LP ($122K), Vanguard Capital Management LLC ($41K) and Vanguard Fiduciary Trust Co. ($19K).
- Company
- Transcode Therapeutics Inc.
- CUSIP
- 89357L501
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $126K |
| Exits | 2 | $110K |
All 13F filers, Q1 2026 → Q2 2026: 20,794 shares bought and 18,155 shares sold, net +2,639 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| Yorkville Advisors Global, LP | 0.14% | New | 19,639 | $122K |
| Vanguard Capital Management LLC | 0.00% | No change | 6,545 | $41K |
| Vanguard Fiduciary Trust Co. | 0.00% | No change | 2,982 | $19K |
| UBS Group AG | 0.00% | Reduce -65.2% | 2,888 | $18K |
| FMR LLC | 0.00% | New | 706 | $4K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +196.9% | 677 | $4K |
| Wells Fargo & Company | 0.00% | No change | 55 | $342 |
| SBI Securities Co., Ltd. | 0.00% | No change | 12 | $75 |
"% of holder's portfolio" is RNAZ's weight in each manager's 13F, not the share of Transcode Therapeutics Inc. the manager owns.